<?xml version='1.0' encoding='utf-8'?>
<document id="27317801"><sentence text="Coproporphyrins in Plasma and Urine Can Be Appropriate Clinical Biomarkers to Recapitulate Drug-Drug Interactions Mediated by Organic Anion Transporting Polypeptide Inhibition."><entity charOffset="0-15" id="DDI-PubMed.27317801.s1.e0" text="Coproporphyrins" /></sentence><sentence text="In the present study, an open-label, three-treatment, three-period clinical study of rosuvastatin (RSV) and rifampicin (RIF) when administered alone and in combination was conducted in 12 male healthy subjects to determine if coproporphyrin I (CP-I) and coproporphyrin III (CP-III) could serve as clinical biomarkers for organic anion transporting polypeptide 1B1 (OATP1B1) and 1B3 that belong to the solute carrier organic anion gene subfamily"><entity charOffset="85-97" id="DDI-PubMed.27317801.s2.e0" text="rosuvastatin" /><entity charOffset="108-118" id="DDI-PubMed.27317801.s2.e1" text="rifampicin" /><entity charOffset="120-123" id="DDI-PubMed.27317801.s2.e2" text="RIF" /><entity charOffset="226-242" id="DDI-PubMed.27317801.s2.e3" text="coproporphyrin I" /><entity charOffset="244-248" id="DDI-PubMed.27317801.s2.e4" text="CP-I" /><entity charOffset="254-272" id="DDI-PubMed.27317801.s2.e5" text="coproporphyrin III" /><entity charOffset="274-280" id="DDI-PubMed.27317801.s2.e6" text="CP-III" /><pair ddi="false" e1="DDI-PubMed.27317801.s2.e0" e2="DDI-PubMed.27317801.s2.e0" /><pair ddi="false" e1="DDI-PubMed.27317801.s2.e0" e2="DDI-PubMed.27317801.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27317801.s2.e0" e2="DDI-PubMed.27317801.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27317801.s2.e0" e2="DDI-PubMed.27317801.s2.e3" /><pair ddi="false" e1="DDI-PubMed.27317801.s2.e0" e2="DDI-PubMed.27317801.s2.e4" /><pair ddi="false" e1="DDI-PubMed.27317801.s2.e0" e2="DDI-PubMed.27317801.s2.e5" /><pair ddi="false" e1="DDI-PubMed.27317801.s2.e0" e2="DDI-PubMed.27317801.s2.e6" /><pair ddi="false" e1="DDI-PubMed.27317801.s2.e1" e2="DDI-PubMed.27317801.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27317801.s2.e1" e2="DDI-PubMed.27317801.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27317801.s2.e1" e2="DDI-PubMed.27317801.s2.e3" /><pair ddi="false" e1="DDI-PubMed.27317801.s2.e1" e2="DDI-PubMed.27317801.s2.e4" /><pair ddi="false" e1="DDI-PubMed.27317801.s2.e1" e2="DDI-PubMed.27317801.s2.e5" /><pair ddi="false" e1="DDI-PubMed.27317801.s2.e1" e2="DDI-PubMed.27317801.s2.e6" /><pair ddi="false" e1="DDI-PubMed.27317801.s2.e2" e2="DDI-PubMed.27317801.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27317801.s2.e2" e2="DDI-PubMed.27317801.s2.e3" /><pair ddi="false" e1="DDI-PubMed.27317801.s2.e2" e2="DDI-PubMed.27317801.s2.e4" /><pair ddi="false" e1="DDI-PubMed.27317801.s2.e2" e2="DDI-PubMed.27317801.s2.e5" /><pair ddi="false" e1="DDI-PubMed.27317801.s2.e2" e2="DDI-PubMed.27317801.s2.e6" /><pair ddi="false" e1="DDI-PubMed.27317801.s2.e3" e2="DDI-PubMed.27317801.s2.e3" /><pair ddi="false" e1="DDI-PubMed.27317801.s2.e3" e2="DDI-PubMed.27317801.s2.e4" /><pair ddi="false" e1="DDI-PubMed.27317801.s2.e3" e2="DDI-PubMed.27317801.s2.e5" /><pair ddi="false" e1="DDI-PubMed.27317801.s2.e3" e2="DDI-PubMed.27317801.s2.e6" /><pair ddi="false" e1="DDI-PubMed.27317801.s2.e4" e2="DDI-PubMed.27317801.s2.e4" /><pair ddi="false" e1="DDI-PubMed.27317801.s2.e4" e2="DDI-PubMed.27317801.s2.e5" /><pair ddi="false" e1="DDI-PubMed.27317801.s2.e4" e2="DDI-PubMed.27317801.s2.e6" /><pair ddi="false" e1="DDI-PubMed.27317801.s2.e5" e2="DDI-PubMed.27317801.s2.e5" /><pair ddi="false" e1="DDI-PubMed.27317801.s2.e5" e2="DDI-PubMed.27317801.s2.e6" /></sentence><sentence text=" Genotyping of the human OATP1B1 gene was performed in all 12 subjects and confirmed absence of OATP1B1*5 and OATP1B1*15 mutations" /><sentence text=" Average plasma concentrations of CP-I and CP-III prior to drug administration were 0"><entity charOffset="34-39" id="DDI-PubMed.27317801.s4.e0" text="CP-I" /><entity charOffset="43-48" id="DDI-PubMed.27317801.s4.e1" text="CP-I" /><pair ddi="false" e1="DDI-PubMed.27317801.s4.e0" e2="DDI-PubMed.27317801.s4.e0" /><pair ddi="false" e1="DDI-PubMed.27317801.s4.e0" e2="DDI-PubMed.27317801.s4.e1" /></sentence><sentence text="91 ± 0" /><sentence text="21 and 0" /><sentence text="15 ± 0" /><sentence text="04 nM, respectively, with minimum fluctuation over the three periods" /><sentence text=" CP-I was passively eliminated, whereas CP-III was actively secreted from urine"><entity charOffset="1-4" id="DDI-PubMed.27317801.s9.e0" text="CP-I" /><entity charOffset="40-43" id="DDI-PubMed.27317801.s9.e1" text="CP-I" /><pair ddi="false" e1="DDI-PubMed.27317801.s9.e0" e2="DDI-PubMed.27317801.s9.e0" /><pair ddi="false" e1="DDI-PubMed.27317801.s9.e0" e2="DDI-PubMed.27317801.s9.e1" /></sentence><sentence text=" Administration of RSV caused no significant changes in the plasma and urinary profiles of CP-I and CP-III"><entity charOffset="91-94" id="DDI-PubMed.27317801.s10.e0" text="CP-I" /><entity charOffset="100-103" id="DDI-PubMed.27317801.s10.e1" text="CP-I" /><pair ddi="false" e1="DDI-PubMed.27317801.s10.e0" e2="DDI-PubMed.27317801.s10.e0" /><pair ddi="false" e1="DDI-PubMed.27317801.s10.e0" e2="DDI-PubMed.27317801.s10.e1" /></sentence><sentence text=" RIF markedly increased the maximum plasma concentration (Cmax) of CP-I and CP-III by 5"><entity charOffset="1-4" id="DDI-PubMed.27317801.s11.e0" text="RIF" /><entity charOffset="67-70" id="DDI-PubMed.27317801.s11.e1" text="CP-I" /><entity charOffset="76-79" id="DDI-PubMed.27317801.s11.e2" text="CP-I" /><pair ddi="false" e1="DDI-PubMed.27317801.s11.e0" e2="DDI-PubMed.27317801.s11.e0" /><pair ddi="false" e1="DDI-PubMed.27317801.s11.e0" e2="DDI-PubMed.27317801.s11.e1" /><pair ddi="false" e1="DDI-PubMed.27317801.s11.e0" e2="DDI-PubMed.27317801.s11.e2" /><pair ddi="false" e1="DDI-PubMed.27317801.s11.e1" e2="DDI-PubMed.27317801.s11.e1" /><pair ddi="false" e1="DDI-PubMed.27317801.s11.e1" e2="DDI-PubMed.27317801.s11.e2" /></sentence><sentence text="7- and 5" /><sentence text="4-fold (RIF) or 5"><entity charOffset="8-11" id="DDI-PubMed.27317801.s13.e0" text="RIF" /></sentence><sentence text="7- and 6" /><sentence text="5-fold (RIF+RSV), respectively, as compared with the predose values"><entity charOffset="8-10" id="DDI-PubMed.27317801.s15.e0" text="RIF" /></sentence><sentence text=" The area under the plasma concentration curves from time 0 to 24 h (AUC0-24h) of CP-I and CP-III with RIF and RSV increased by 4"><entity charOffset="103-105" id="DDI-PubMed.27317801.s16.e0" text="RIF" /><entity charOffset="82-84" id="DDI-PubMed.27317801.s16.e1" text="CP-I" /><entity charOffset="91-93" id="DDI-PubMed.27317801.s16.e2" text="CP-I" /><pair ddi="false" e1="DDI-PubMed.27317801.s16.e1" e2="DDI-PubMed.27317801.s16.e1" /><pair ddi="false" e1="DDI-PubMed.27317801.s16.e1" e2="DDI-PubMed.27317801.s16.e2" /><pair ddi="false" e1="DDI-PubMed.27317801.s16.e1" e2="DDI-PubMed.27317801.s16.e0" /><pair ddi="false" e1="DDI-PubMed.27317801.s16.e2" e2="DDI-PubMed.27317801.s16.e2" /><pair ddi="false" e1="DDI-PubMed.27317801.s16.e2" e2="DDI-PubMed.27317801.s16.e0" /></sentence><sentence text="0- and 3" /><sentence text="3-fold, respectively, when compared with RSV alone" /><sentence text=" In agreement with this finding, Cmax and AUC0-24h of RSV increased by 13" /><sentence text="2- and 5" /><sentence text="0-fold, respectively, when RIF was coadministered"><entity charOffset="27-30" id="DDI-PubMed.27317801.s21.e0" text="RIF" /></sentence><sentence text=" Collectively, we conclude that CP-I and CP-III in plasma and urine can be appropriate endogenous biomarkers specifically and reliably reflecting OATP inhibition, and thus the measurement of these molecules can serve as a useful tool to assess OATP drug-drug interaction liabilities in early clinical studies"><entity charOffset="32-34" id="DDI-PubMed.27317801.s22.e0" text="CP-I" /><entity charOffset="41-43" id="DDI-PubMed.27317801.s22.e1" text="CP-I" /><pair ddi="false" e1="DDI-PubMed.27317801.s22.e0" e2="DDI-PubMed.27317801.s22.e0" /><pair ddi="false" e1="DDI-PubMed.27317801.s22.e0" e2="DDI-PubMed.27317801.s22.e1" /></sentence><sentence text=" " /></document>